<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55000349"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<docTitle>
	<titlePart>Discovery of an Opioid K Receptor Selective Pure Antagonist from a Library of<lb/> N-Substituted 4-Methyl-5-(3-hydroxyphenyl)morphans<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>James B. Thomas, Robert N. Atkinson, Nivedita Namdev, Richard B. Rothman, Kenneth M. Gigstad,<lb/> Scott E. Fix, S. Wayne Mascarella, Jason P. Burgess, N. Ariane Vinson, Heng Xu, Christina M. Dersch,<lb/> Buddy E. Cantrell, Dennis M. Zimmerman, and F. Ivy Carroll* ,<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Chemistry and Life Sciences, Research Triangle Institute,</affiliation>
	</byline>

	<address>Research Triangle Park, North Carolina 27709, Clinical<lb/></address>

	<byline>
	<affiliation>Psychopharmacology Section, NIDA Addiction Research Section,</affiliation>
	</byline>

	<address>P.O. Box 5180, Building C, 4980 Eastern Avenue,<lb/> Baltimore, Maryland 21224,</address>

	<byline>
	<affiliation>and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center,<lb/></affiliation>
	</byline>

	<address>Indianapolis, Indiana 4628<lb/></address>

	<note type="submission">Received February 20, 2002<lb/></note>

	<div type="abstract">A library of compounds biased toward opioid receptor antagonist activity was prepared by<lb/> incorporating N-phenylpropyl-4-methyl-5-(3-hydroxyphenyl)morphans as the core scaffold<lb/> using simultaneous solution phase synthetic methodology. From this library, N-phenylpropyl-<lb/>4-methyl-5-(3-hydroxyphenyl)-7R-[3-(1-piperidinyl)propanamido]morphan [(-)-3b] was identi-<lb/>fied as the first potent and selective Îº opioid receptor antagonist from the 5-phenylmorphan<lb/> class of opioids.<lb/></div>

		</front>
	</text>
</tei>
